A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
复制标题

全基因组的RNAi筛查鉴定了与RAS癌基因的多种合成致死相互作用。

DOI:
10.1016/j.cell.2009.05.006
复制
发表时间:
2009-05-29
期刊:
影响因子:
64.5
通讯作者:
Elledge SJ
Elledge SJ
中科院分区:
生物学1区
文献类型:
--
作者:
Luo J;Emanuele MJ;Li D;Creighton CJ;Schlabach MR;Westbrook TF;Wong KK;Elledge SJ

文献摘要

参考文献

被引文献

相似文献

小GT3 Ras的致癌突变在癌症中非常普遍,但对这些癌症的脆弱性缺乏了解。我们进行了全基因组RNAi筛选,以确定与KRAS癌基因的合成致死相互作用。我们发现了一组不同的蛋白质,其消耗选择性地损害Ras突变细胞的活力。其中,我们观察到一个强大的富集有丝分裂功能的基因。我们描述了一个途径,涉及有丝分裂激酶PLK 1,后期促进复合物/细胞周期体和蛋白酶体,当抑制,结果在前中期积累和随后的死亡Ras突变细胞。基因表达分析表明,该途径中基因表达的减少与携带具有Ras转录特征的肿瘤的患者的存活率增加相关。我们的研究结果表明,以前低估的作用,Ras在有丝分裂的进展,并证明了一个易处理的途径,为潜在的治疗癌症窝藏Ras突变。
Oncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understanding of the vulnerabilities of these cancers is lacking. We undertook a genome-wide RNAi screen to identify synthetic lethal interactions with the KRAS oncogene. We discovered a diverse set of proteins whose depletion selectively impaired the viability of Ras mutant cells. Among these we observed a strong enrichment for genes with mitotic functions. We describe a pathway involving the mitotic kinase PLK1, the anaphase promoting complex/cyclosome and the proteasome that, when inhibited, results in prometaphase accumulation and the subsequent death of Ras mutant cells. Gene expression analysis indicates that reduced expression of genes in this pathway correlates with increased survival of patients bearing tumors with a Ras transcriptional signature. Our results suggest a previously underappreciated role for Ras in mitotic progression and demonstrate a pharmacologically tractable pathway for the potential treatment of cancers harboring Ras mutations.
DOI: 10.1182/blood.v88.7.2699.bloodjournal8872699
发表时间: 1996-10-01
期刊: BLOOD
影响因子: 20.3
作者:
Liu, PC;Leong, T;VanNess, B
通讯作者: VanNess, B
有效使用 PI3K 和 MEK 抑制剂治疗突变型 Kras G12D 和 PIK3CA H1047R 小鼠肺癌。
DOI: 10.1038/nm.1890
发表时间: 2008-12
期刊: Nature medicine
影响因子: 82.9
作者:
通讯作者: --
DOI: 10.1016/j.cell.2005.10.038
发表时间: 2006-01-27
期刊: CELL
影响因子: 64.5
作者:
Eldridge, AG;Loktev, AV;Jackson, PK
通讯作者: Jackson, PK
DOI: 10.1038/nm733
发表时间: 2002-08-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Beer, DG;Kardia, SLR;Hanash, S
通讯作者: Hanash, S
DOI: 10.1038/nature07185
发表时间: 2008-09-04
期刊: NATURE
影响因子: 64.8
作者:
Macurek, Libor;Lindqvist, Arne;Medema, Rene H.
通讯作者: Medema, Rene H.